Hematologic Oncology

At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm.

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.

Samer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.

Praveen Ramakrishnan, MD, assistant professor, Department of Internal Medicine, UT Southwestern Medical Center, discusses updates in diffuse large B-cell lymphoma (DLBCL) that were presented at the 2019 ASH Annual Meeting.

Benjamin Heyman, MD, assistant clinical professor of medicine, University of California, San Diego, discusses the use of maintenance rituximab (Rituxan) in patients with follicular lymphoma.

Newly approved and investigational agents are joining ruxolitinib for the treatment of myelofibrosis and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

Jae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

Gemtuzumab ozogamicin in combination with intensive induction therapy was associated with a higher early death rate compared with induction therapy alone in patients with NPM1-mutated acute myeloid leukemia.

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

Benjamin Heyman, MD, discusses frontline and maintenance therapy options, novel targeted approaches, and the expanding role of minimal residual disease in patients with follicular lymphoma.

Ayad Hamdan, MD, discusses the impact of the 4-year follow-up data from the ECHELON-1 trial in advanced-stage Hodgkin lymphoma.

Madhuri Vusirikala, MD, discusses the benefit of hyper-CVAD and ponatinib in patients with Philadelphia chromosome–positive ALL.

Caitlin Costello, MD, discusses pivotal research in the relapsed/refractory multiple myeloma setting.

The selective ROCK2 inhibitor KD025 induced clinical responses in approximately two-thirds of patients with chronic graft-versus-host disease, including complete responses in 3 patients.

Dimitrios Tzachanis, MD, PhD, discusses updates and remaining questions with CAR T-cell therapy.

Erin Reid, MD, discusses the treatment advances across lymphomas and the remaining questions that need to be answered with further research.

Anthony D. Sung, MD, discusses the findings from the phase II trial of pasireotide as a method to prevent gastrointestinal toxicity and acute graft-versus-host-disease in patients who undergo allogeneic hematopoietic stem cell transplant.

Narsoplimab (OMS721) is advancing through the therapy pipeline as a novel treatment option for patients with transplant-associated thrombotic microangiopathy.

An “off-the-shelf” Epstein Barr-virus–specific cytotoxic lymphocyte CAR product derived from cells harvested from third-party donors induced a 100% response rate in adult and pediatric patients with relapsed/refractory non-Hodgkin lymphoma.

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.

Iodine (131I) apamistamab (Iomab-B) conditioning induced a complete remission in 84% (31/38) of patients with active acute myeloid leukemia, who were then able to receive allogeneic hematopoietic stem cell transplant, according to preliminary results from the phase III SIERRA trial.

Aaron Goodman, MD, discusses recent changes to the frontline treatment of patients with peripheral T-cell lymphoma and the challenges of targeting T-cell lymphoma.

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Benjamin Heyman, MD, discusses frontline treatment options for patients with follicular lymphoma.

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.

Outpatient administration of CAR T-Cell therapy is safe and effective, according to an analysis of 3 studies of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Diego Villa, MD, MPH, discusses the benefit of bendamustine and rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.